Xuewei Bai

Dr. Xuewei Bai


Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 October 2021 in Cell Death & Disease
Verified
Journal Article
Open access
PDF file
TZTao Zhang
Tao Zhang
GZGuangquan Zhang
Guangquan Zhang
WYWenbo Yang
Wenbo Yang
HCHongze Chen
Hongze Chen
JHJisheng Hu
Jisheng Hu
LLLe Li
Le Li
Chronic pancreatitis (CP) is described as progressive inflammatory fibrosis of pancreas, accompanied with irreversible impaired endocrine and exocrine insufficiency. Pancreatic stellate cells (PSCs) are widely distributed in the stroma of the pancreas and PSCs activation has been shown as one of the leading causes for pancreatic fibrosis. Our previous study has revealed that autophagy is dramatically activated in CP tissues, which facilitates PSCs activation and pancreatic fibrosis. Long non-coding RNAs (LncRNAs) have been recognized as crucial regulators for fibrosis-related diseases. LncRNAs interact with RNA binding protein or construct competitive endogenous RNA (ceRNA) hypothesis which elicited the fibrotic processes. Until now, the effects of lncRNAs on PSCs activation and pancreatic fibrosis have not been clearly explored. In this study, a novel lncRNA named Lnc-PFAR was found highly expressed in mouse and human CP tissues. Our data revealed that Lnc-PFAR facilitates PSCs activation and pancreatic fibrosis via RB1CC1-induced autophagy. Lnc-PFAR reduces miR-141 expression by suppressing pre-miR-141 maturation, which eventually upregulates the RB1CC1 and fibrosis-related indicators expression. Meanwhile, Lnc-PFAR enhanced PSCs activation and pancreatic fibrosis through trigging autophagy. Our study interrogates a novel lncRNA-induced mechanism in promoting the development of pancreatic fibrosis, and Lnc-PFAR is suggested to be a prospective therapeutic target in clinical scenarios.

16 June 2023 in Journal of Pancreatology
Verified
Journal Article
Open access
ZDZu-Chao Du
Zu-Chao Du
GLGuan-Qun Li
Guan-Qun Li
YLYan Luo
Yan Luo
XBXuewei Bai
Xuewei Bai
BSBei Sun
Bei Sun
Acute pancreatitis (AP) is one of the most common acute abdomen diseases with increasing incidence and substantial healthcare burden. Gut microbiota disturbance, mucosal barrier failure, and bacterial translocation are identified as the dominant cause of infected pancreatic necrosis and high mortality. With the advance of high-throughput sequencing, imbalance between beneficial and facultative pathogenic microorganisms with their metabolic activities in the development of AP has been increasingly recognized, whereas it remains unclear whether dysbacteriosis is the dominant cause of aggravating AP, or merely reflecting different epidemiological or environmental factors at the individual level. This review discussed the alterations of the gut microbiota and their metabolites during AP with detailed molecular mechanisms. Importantly, it highlights microbiome-based medical therapies which influence gut barrier function and immune homeostasis to mitigate inflammatory responses in AP. Our review will provide a novel roadmap of gastrointestinal microecology in AP progression, and contribute to the future development of microbiome-based diagnostic and therapeutic strategies in clinical practice.

1 January 2022 in Therapeutic Advances in Gastroenterology
Verified
Journal Article
Open access
ZDZu-Chao Du
Zu-Chao Du
JZJian Zhang
Jian Zhang
XLXin-Jian Li
Xin-Jian Li
ZZZhan-Tian Zhang
Zhan-Tian Zhang
KBKai-Song Bai
Kai-Song Bai
BSBei Sun
Bei Sun
Background: Since initially detected in late December 2019, the novel coronavirus disease 2019 (COVID-19) outbreak rapidly swept the world, which has profoundly affected healthcare system and clinical practice in the management of gastrointestinal diseases. Objectives: We aimed to evaluate the impact of COVID-19 pandemic on the pattern of hospital admissions and healthcare services for acute pancreatitis (AP). Design: We conducted a retrospective observational cohort study using the anonymized electronic medical records. Methods: This single-center, retrospective observational study from a regional medical center in the northeast of China included all consecutively admitted patients with AP from 23 January to 10 June 2020 (during the COVID-19 outbreak in Harbin), compared with the equivalent period of the previous year, in terms of demographics, clinical characteristics, and in-hospital outcomes. Results: In this article, we observed a reduction in AP admissions after the beginning of COVID-19 outbreak. With the prolonged time from symptom onset to hospitalization [32.0 (22.0–72.0) versus 18.0 (12.0–24.0) h; p < 0.001], a higher proportion of AP patients developed acute renal failure (14.0% versus 7.4%, p = 0.004) and acute necrotic collection (16.5% versus 11.2%; p = 0.038) in the COVID-19 era. The percentage of alcohol etiology significantly decreased after the implementation of social restriction measures (11.5% versus 20.4%; p = 0.002), whereas biliary etiology was numerically more common amidst the COVID-19 era (41.6% versus 32.6%; p = 0.014). No significant differences were found in the rates of intensive care unit admission and mortality between the two groups. Conclusion: This study preliminarily demonstrated the descending trend and delay in hospital presentations for AP during the outbreak of COVID-19. Given that the pandemic may persist for several years, adjustments of medical services according to the varying degrees of local breakouts are imperative to provide appropriate care for AP patients and diminish the risk of viral transmission. Registration: ClincialTrials.gov number ChiCTR2100043350.

1 January 2017 in World Chinese Journal of Digestology
Verified
Journal Article
Open access
XWXiao-Qian Wang
Xiao-Qian Wang
BSBei Sun
Bei Sun
LLLe Li
Le Li
XBXuewei Bai
Xuewei Bai
高脂血症(hyperlipidemia, HL)与急性胰腺炎(acute pancreatitis, AP)之间的关系已成为胰腺疾病研究的热点. HL可能诱发AP, AP发生时也可能伴有脂类的代谢紊乱, 因此HL与AP可互为因果. HL包括高甘油三酯血症(hypertriglyceridemia, HTG)与高胆固醇血症(hypercholesterolemia, HTC)两类, 其中HTG作为AP的病因已经获得了国内外学者的公认, 而HTC是否可以引起AP的发生则尚未达成共识. 高脂血症性急性胰腺炎(hyperlipidemic acute pancreatitis, HLAP)的诊断除需满足AP的诊断外还要结合血脂水平而定, 但关于诊断HLAP的血脂水平的确定, 目前国内外仍未达成一致意见. 由于HLAP的诊断标准决定了诊治方案的选择并影响患者的预后, 因此统一的诊断标准的缺失使得HLAP的临床诊治工作仍面临着巨大的困难和挑战.

9 September 2021 in Frontiers in Genetics
Verified
Journal Article
Open access
KBKaisong Bai
Kaisong Bai
TZTong Zhao
Tong Zhao
YLYilong Li
Yilong Li
XLXinjian Li
Xinjian Li
ZZZhantian Zhang
Zhantian Zhang
XBXuewei Bai
Xuewei Bai
Pancreatic adenocarcinoma (PAAD) is one of the deadliest malignancies and mortality for PAAD have remained increasing under the conditions of substantial improvements in mortality for other major cancers. Although multiple of studies exists on PAAD, few studies have dissected the oncogenic mechanisms of PAAD based on genomic variation. In this study, we integrated somatic mutation data and gene expression profiles obtained by high-throughput sequencing to characterize the pathogenesis of PAAD. The mutation profile containing 182 samples with 25,470 somatic mutations was obtained from The Cancer Genome Atlas (TCGA). The mutation landscape was generated and somatic mutations in PAAD were found to have preference for mutation location. The combination of mutation matrix and gene expression profiles identified 31 driver genes that were closely associated with tumor cell invasion and apoptosis. Co-expression networks were constructed based on 461 genes significantly associated with driver genes and the hub gene FAM133A in the network was identified to be associated with tumor metastasis. Further, the cascade relationship of somatic mutation-Long non-coding RNA (lncRNA)-microRNA (miRNA) was constructed to reveal a new mechanism for the involvement of mutations in post-transcriptional regulation. We have also identified prognostic markers that are significantly associated with overall survival (OS) of PAAD patients and constructed a risk score model to identify patients’ survival risk. In summary, our study revealed the pathogenic mechanisms and prognostic markers of PAAD providing theoretical support for the development of precision medicine.

13 August 2020 in American Journal of Gastroenterology
Verified
Journal Article
Closed access
ZDZu-Chao Du
Zu-Chao Du
XLXin-Jian Li
Xin-Jian Li
ZZZhan-Tian Zhang
Zhan-Tian Zhang
YZYan-Mei Zhou
Yan-Mei Zhou
KBKai-Song Bai
Kai-Song Bai
XBXuewei Bai
Xuewei Bai